METTL3 and hepatocellular carcinoma: In sorafenib-resistant hepatocellular carcinoma, METTL3 was significantly down-regulated and could promote m6A modification of FOXO3 3’UTR increasing its stability via recruiting YTHDF1, thereby enhancing sorafenib resistance of HCC [46].